| Literature DB >> 30301216 |
Qing Yao1, Meng-Ting Lin2, Yin-Di Zhu3, He-Lin Xu4, Ying-Zheng Zhao5.
Abstract
Didymin (isosakuranetin 7-O-rutinoside) is an orally bioactive dietary flavonoid glycoside first found in citrus fruits. Traditionally, this flavonoid has long been used in Asian countries as a dietary antioxidant. Recent studies have provided newer insights into this pleiotropic compound, which could regulate multiple biological activities of many important signaling molecules in health and disease. Emerging data also presented the potential therapeutic application of dietary flavonoid glycoside didymin against cancer, neurological diseases, liver diseases, cardiovascular diseases, and other diseases. In this review, we briefly introduce the source and extraction methods of didymin, and summarize its potential therapeutic application in the treatment of various diseases, with an emphasis on molecular targets and mechanism that contributes to the observed therapeutic effects. The dietary flavonoid didymin can be used to affect health and disease with multiple therapeutic targets, and it is anticipated that this review will stimulate the future development of this potential dietary medicine.Entities:
Keywords: cancer; didymin; dietary flavonoid glycoside; neurodegenerative disorders; therapeutic effects
Mesh:
Substances:
Year: 2018 PMID: 30301216 PMCID: PMC6222367 DOI: 10.3390/molecules23102547
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure and basic properties of didymin. (A) The chemical structure of didymin. (B) Major physical and chemical properties.
The source and extraction separation method of didymin.
| Didymin is a Flavonoid Glycoside Commonly Found in Citrus Fruits | |
|---|---|
| Source | Orange [ |
| Grapefruit [ | |
| Mandarin [ | |
| Bergamot [ | |
| Other citrus [ | |
|
| |
| Extraction and Detection Method | MS-HPLC [ |
| Ultra-HPLC (UHPLC) [ | |
| Comprehensive multidimensional LC methods [ | |
| RP-HPLC and photodiode array detection [ | |
| Nano-LC/UV-Vis apparatus [ | |
| UAE [ | |
| UPLC-ESI-QTOF-MS/MS [ | |
Figure 2Therapeutic application of didymin in promoting the health. The green arrow indicates the promoted effect of didymin. The red arrow indicates the inhibitory effect of didymin.
Different diseases and mechanism study related to didymin.
| Disease | Mechanism Studies | Ref. |
|---|---|---|
| Lung cancer | The primary pathway of apoptosis induced by didymin is the Fas/Fas ligand apoptotic system, which does not mediate p53 and p21/WAF1. | [ |
| Neuroblastoma | Inhibition of N-Myc transcription, up-regulated RKIP and down-regulated PI13K, Akt and vimentin. | [ |
| Downregulation of cyclin D1, cyclin B1, CDK4, CD31, Ki67, and N-Myc also enhance the anti-tumor effect of didymin. | ||
| Breast cancer | Didymin can effectively inhibit phthalate-mediated invasion, migration, and proliferation of breast cancer cells. | [ |
| Neurodegenerative disease | Removing excess ROS or inhibiting its production by antioxidant molecules could effectively maintain cell redox homeostasis and prevent oxidative damage. | [ |
| Effectively inhibits apoptosis and activates antioxidant defense enzymes. | ||
| Sleeplessness | GABAergic system participation in the anxiolytic actions of didymin. | [ |
| Hepatic diseases | Didymin has antioxidant activity, scavenges free radicals, and regulates MAPK and NF-κB signaling pathways. | [ |
| Cardiovascular complications | Didymin prevented HG-induced (ROS) and the production of lipid peroxidation product malondialdehyde and prevented HG-induced monocyte-endothelial cell adhesion, ICAM-1 and VCAM-1 expression, and NF-κB activation. | [ |
| Didymin inhibits the release of various inflammatory cytokines and chemokines from HG-treated HUVECs. |
Figure 3Didymin is involved in lung cancer cell signaling pathways. The main pathway of apoptosis of A549 and H460 cells induced by didymin is the Fas/Fas ligand apoptotic system. Fas is a cell surface receptor when its ligand (FasL) recognizes and activates Fas; it leads to oligomerization of the intracellular death domain and recruitment of the intracellular adaptor Fas-associated death domain (FADD). After binding, FADD can activate procaspase-8 and procaspase-10 in the death-inducing signaling complex, causing A549 and H460 cells apoptosis or death without the mediation of p53 and p21/WAF1.
Figure 4Didymin affects neuroblastoma signaling pathways. Stimulating the expression of RKIP is a key role for didymin to exert its efficacy. Also, didymin inhibits N-Myc transcription, on the other hand, didymin decreases the expression levels of PI3K, Akt, vimentin, and down-regulates cyclin D1, B1, and CDK4. By staining the pathological sections of the tumor tissue, didymin not only reduced the expression of the angiogenesis marker CD31 in vivo but also inhibited the expression of the proliferation markers Ki67 and N-Myc. The blue arrow indicates normal signal transduction, the green arrow indicates enhancement, and the red arrow represents inhibition.